Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline ...

Exelixis, Inc. EXEL reported preliminary, unaudited financial results for fiscal year 2025, issued financial guidance for ...

Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the stage for submissions of robust clinical data ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been ...

Biocon Biologics plans to introduce three oncology biosimilars, enhancing its cancer treatment portfolio. They will unveil ...

In a judgment of far-reaching significance for India's pharmaceutical and patent jurisprudence, the Delhi High Court has ...

The Delhi High Court recently held that public interest is an important consideration while deciding whether to grant an ...